Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients

Hepatotoxicity and effectiveness

Jose Cadenazuluaga, Deborah J Levine, L. F. Angel, P. R. Maxwell, R. Brady, J. F. Sanchez, Joel E Michalek, Stephanie M Levine, Marcos Restrepo

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Invasive fungal infections (IFI) are common after lung transplantation and there are limited data for the use of antifungal prophylaxis in these patients. Our aim was to compare the safety and describe the effectiveness of universal prophylaxis with two azole regimens in lung transplant recipients. This is a retrospective study in lung transplant recipients from July 2003 to July 2006 who received antifungal prophylaxis with itraconazole or voriconazole plus inhaled amphotericin B to compare the incidence of hepatotoxicity. Secondary outcomes include describing the incidence of IFI, clinical outcomes after IFI and mortality. Sixty-seven consecutive lung transplants received antifungal prophylaxis, 32 itraconazole and 35 voriconazole and inhaled amphotericin B. There were no significant differences between groups in the acute physiology and chronic health evaluation (APACHE) score at the time of transplantation, demographic characteristics, comorbidities and concomitant use of hepatotoxic medications. Hepatotoxicity occurred in 12 patients receiving voriconazole and inhaled amphotericin B and in no patients receiving itraconazole (p < 0.001). There was no significant difference between groups with regard to the percentage of transplants with IFI, but one case of zygomycosis occurred in a transplant treated with voriconazole. Voriconazole prophylaxis after lung transplantation was associated with a higher incidence of hepatotoxicity and similar clinical effectiveness when compared to itraconazole.

Original languageEnglish (US)
Pages (from-to)2085-2091
Number of pages7
JournalAmerican Journal of Transplantation
Volume9
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Itraconazole
Amphotericin B
Lung
Lung Transplantation
Transplants
Incidence
Zygomycosis
Azoles
APACHE
Comorbidity
Retrospective Studies
Transplantation
Demography
Transplant Recipients
Voriconazole
Safety
Mortality
Invasive Fungal Infections

Keywords

  • Aspergillus
  • Itraconazole
  • Lung transplantation
  • Prophylaxis
  • Voriconazole

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients : Hepatotoxicity and effectiveness. / Cadenazuluaga, Jose; Levine, Deborah J; Angel, L. F.; Maxwell, P. R.; Brady, R.; Sanchez, J. F.; Michalek, Joel E; Levine, Stephanie M; Restrepo, Marcos.

In: American Journal of Transplantation, Vol. 9, No. 9, 09.2009, p. 2085-2091.

Research output: Contribution to journalArticle

Cadenazuluaga, Jose ; Levine, Deborah J ; Angel, L. F. ; Maxwell, P. R. ; Brady, R. ; Sanchez, J. F. ; Michalek, Joel E ; Levine, Stephanie M ; Restrepo, Marcos. / Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients : Hepatotoxicity and effectiveness. In: American Journal of Transplantation. 2009 ; Vol. 9, No. 9. pp. 2085-2091.
@article{58266ad955da49639d227bc0bec20ddd,
title = "Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: Hepatotoxicity and effectiveness",
abstract = "Invasive fungal infections (IFI) are common after lung transplantation and there are limited data for the use of antifungal prophylaxis in these patients. Our aim was to compare the safety and describe the effectiveness of universal prophylaxis with two azole regimens in lung transplant recipients. This is a retrospective study in lung transplant recipients from July 2003 to July 2006 who received antifungal prophylaxis with itraconazole or voriconazole plus inhaled amphotericin B to compare the incidence of hepatotoxicity. Secondary outcomes include describing the incidence of IFI, clinical outcomes after IFI and mortality. Sixty-seven consecutive lung transplants received antifungal prophylaxis, 32 itraconazole and 35 voriconazole and inhaled amphotericin B. There were no significant differences between groups in the acute physiology and chronic health evaluation (APACHE) score at the time of transplantation, demographic characteristics, comorbidities and concomitant use of hepatotoxic medications. Hepatotoxicity occurred in 12 patients receiving voriconazole and inhaled amphotericin B and in no patients receiving itraconazole (p < 0.001). There was no significant difference between groups with regard to the percentage of transplants with IFI, but one case of zygomycosis occurred in a transplant treated with voriconazole. Voriconazole prophylaxis after lung transplantation was associated with a higher incidence of hepatotoxicity and similar clinical effectiveness when compared to itraconazole.",
keywords = "Aspergillus, Itraconazole, Lung transplantation, Prophylaxis, Voriconazole",
author = "Jose Cadenazuluaga and Levine, {Deborah J} and Angel, {L. F.} and Maxwell, {P. R.} and R. Brady and Sanchez, {J. F.} and Michalek, {Joel E} and Levine, {Stephanie M} and Marcos Restrepo",
year = "2009",
month = "9",
doi = "10.1111/j.1600-6143.2009.02734.x",
language = "English (US)",
volume = "9",
pages = "2085--2091",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients

T2 - Hepatotoxicity and effectiveness

AU - Cadenazuluaga, Jose

AU - Levine, Deborah J

AU - Angel, L. F.

AU - Maxwell, P. R.

AU - Brady, R.

AU - Sanchez, J. F.

AU - Michalek, Joel E

AU - Levine, Stephanie M

AU - Restrepo, Marcos

PY - 2009/9

Y1 - 2009/9

N2 - Invasive fungal infections (IFI) are common after lung transplantation and there are limited data for the use of antifungal prophylaxis in these patients. Our aim was to compare the safety and describe the effectiveness of universal prophylaxis with two azole regimens in lung transplant recipients. This is a retrospective study in lung transplant recipients from July 2003 to July 2006 who received antifungal prophylaxis with itraconazole or voriconazole plus inhaled amphotericin B to compare the incidence of hepatotoxicity. Secondary outcomes include describing the incidence of IFI, clinical outcomes after IFI and mortality. Sixty-seven consecutive lung transplants received antifungal prophylaxis, 32 itraconazole and 35 voriconazole and inhaled amphotericin B. There were no significant differences between groups in the acute physiology and chronic health evaluation (APACHE) score at the time of transplantation, demographic characteristics, comorbidities and concomitant use of hepatotoxic medications. Hepatotoxicity occurred in 12 patients receiving voriconazole and inhaled amphotericin B and in no patients receiving itraconazole (p < 0.001). There was no significant difference between groups with regard to the percentage of transplants with IFI, but one case of zygomycosis occurred in a transplant treated with voriconazole. Voriconazole prophylaxis after lung transplantation was associated with a higher incidence of hepatotoxicity and similar clinical effectiveness when compared to itraconazole.

AB - Invasive fungal infections (IFI) are common after lung transplantation and there are limited data for the use of antifungal prophylaxis in these patients. Our aim was to compare the safety and describe the effectiveness of universal prophylaxis with two azole regimens in lung transplant recipients. This is a retrospective study in lung transplant recipients from July 2003 to July 2006 who received antifungal prophylaxis with itraconazole or voriconazole plus inhaled amphotericin B to compare the incidence of hepatotoxicity. Secondary outcomes include describing the incidence of IFI, clinical outcomes after IFI and mortality. Sixty-seven consecutive lung transplants received antifungal prophylaxis, 32 itraconazole and 35 voriconazole and inhaled amphotericin B. There were no significant differences between groups in the acute physiology and chronic health evaluation (APACHE) score at the time of transplantation, demographic characteristics, comorbidities and concomitant use of hepatotoxic medications. Hepatotoxicity occurred in 12 patients receiving voriconazole and inhaled amphotericin B and in no patients receiving itraconazole (p < 0.001). There was no significant difference between groups with regard to the percentage of transplants with IFI, but one case of zygomycosis occurred in a transplant treated with voriconazole. Voriconazole prophylaxis after lung transplantation was associated with a higher incidence of hepatotoxicity and similar clinical effectiveness when compared to itraconazole.

KW - Aspergillus

KW - Itraconazole

KW - Lung transplantation

KW - Prophylaxis

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=69149096653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149096653&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02734.x

DO - 10.1111/j.1600-6143.2009.02734.x

M3 - Article

VL - 9

SP - 2085

EP - 2091

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 9

ER -